Current Report Filing (8-k)
15 April 2022 - 7:13AM
Edgar (US Regulatory)
0001427570
false
0001427570
2022-04-08
2022-04-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
April 8, 2022
RESHAPE LIFESCIENCES
INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
1-37897 |
26-1828101 |
|
(State or other jurisdiction
of incorporation) |
(Commission
File Number) |
(I.R.S. Employer
Identification Number) |
|
|
|
|
1001 Calle Amanecer
San Clemente, CA |
92673 |
(Address of principal executive offices) |
(Zip Code) |
|
|
|
|
|
(949) 429-6680
(Registrant’s
telephone number, including area code)
Not applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title
of Class |
Trading
Symbol |
Name
of Exchange on which Registered |
Common stock, $0.001 par value per share |
RSLS |
The Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 4.01 Changes
in Registrant’s Certifying Accountant.
On
April 8, 2022, BDO USA, LLP (“BDO”) resigned as the independent registered public accounting firm of Reshape Lifesciences
Inc. (the “Company”) effective upon the date of filing of the Company’s Form 10-Q for the quarter ended March 31, 2022.
BDO’s report on the Company’s financial
statements the fiscal years ended December 31, 2021 and 2020 did not contain an adverse opinion or a disclaimer of opinion, or was qualified
or modified as to uncertainty, audit scope, or accounting principles.
During the fiscal years ended December 31, 2021
and 2020, and through the interim period ended April 8, 2022, there were no disagreements with BDO on any matter of accounting principles
or practices, financial statement disclosure, or auditing scope or procedure, which, if not resolved to BDO’s satisfaction, would
have caused it to make reference to the subject matter of the disagreement(s) in connection with its report on any of the Company’s
financial statements for such periods.
During the fiscal years ended December 31, 2021
and 2020 and the subsequent interim period through April 8, 2022, there were no reportable events (as that term is described in Item 304(a)(1)(v) of Regulation
S-K).
The Company has provided BDO with a copy of the
foregoing disclosures and requested that BDO furnish the Company with a letter addressed to the Securities and Exchange Commission stating
whether or not it agrees with the foregoing disclosures. A copy of the letter from BDO to the Securities and Exchange Commission is attached
hereto as Exhibit 16.1.
The Company has not engaged a new independent
registered public accounting firm as of the date of this report. The Company will disclose its engagement of a new independent registered
public accounting firm once the process has been completed and as required by the SEC’s rules and regulations.
Item 9.01 Financial
Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
RESHAPE LIFESCIENCES INC. |
|
|
|
|
By: |
/s/ Tom Stankovich |
|
|
Tom Stankovich |
|
|
Chief Financial Officer |
Dated: April 14, 2022
ReShape Lifesciences (NASDAQ:RSLS)
Historical Stock Chart
From Apr 2024 to May 2024
ReShape Lifesciences (NASDAQ:RSLS)
Historical Stock Chart
From May 2023 to May 2024